Background:Answering
the question of what is the optimal protocol for monitoring controlled ovarian
stimulation (COS) still remains a challenge. The rapid introduction of new
diagnostic methods and various components of telemedicine makes it possible to
reduce the number of patient visits during ovarian stimulation, which will
reduce the loss of time, costs, and risk for the patient from COVID-like
situations. Methods:The different COS monitoring protocols are examined, thus proposing a new
approach consisting of two successive phases. Results: In the first
phase, E3G in urine samples is being examined, which is performed by the
patient themselves with a small portable analyzer. Based on the results, the
specialist prescribes the doses for stimulation. The second phase involves one
single determination of the size and number of follicles at the end of
stimulation, using TVUS, as well as the dynamics of serum levels of P4 and E2.
This proves to be in many cases sufficient. Conclusions:It is of
our opinion that on the basis of new diagnostic tests such as E3G in urine and
telemedicine, patients are able to independently and actively participate in
the treatment process. This new approach to COS monitoring can be successfully
implemented in different protocols for ovarian stimulation.
References
[1]
Confino, E., Binor, Z., Molo, M.W., Rawlins, R., Balos, R., Mullaney, K. and Radwanska, E. (1996) Sonographically Monitored Ovarian Stimulation for Assisted Reproduction: A Prospective, Blind Study. Journal of Reproductive Medicine, 41, 7-10.
[2]
Lass, A. (2003) Monitoring of in Vitro Fertilization—Embryo Transfer Cycles by Ultrasound versus by Ultrasound and Hormonal Levels: A Prospective, Multicenter, Randomized Study. Fertility and Sterility, 80, 80-85.
https://doi.org/10.1016/S0015-0282(03)00558-2
[3]
Martins, W.P., Vieira, C.V.R., Teixeira, D.M., Barbosa, M.A.P., Dassunção, L.A. and Nastri, C.O. (2014) Ultrasound for Monitoring Controlled Ovarian Stimulation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Ultrasound in Obstetrics & Gynecology, 43, 25-33. https://doi.org/10.1002/uog.12566
[4]
Farquhar, C., Marjoribanks, J., Brown, J., Fauser, B., Lethaby, A., Mourad, S., Rebar, R., Showell, M. and van der Poel, S. (2017) Management of Ovarian Stimulation for IVF: Narrative Review of Evidence Provided for World Health Organization Guidance. Reproductive Biomedicine Online, 35, 3-16.
https://doi.org/10.1016/j.rbmo.2017.03.024
[5]
Dorsey, E.R. and Topol, E.J. (2016) State of Telehealth. The New England Journal of Medicine, 375, 154-161. https://doi.org/10.1056/NEJMra1601705
[6]
Rashid, L., Bashshur, R.L., Shannon, G.W., Smith, B.R. and Woodward, M.A. (2015) The Empirical Evidence for the Telemedicine Intervention in Diabetes Management. Telemedicine Journal and e-Health, 21, 321-354.
https://doi.org/10.1089/tmj.2015.0029
[7]
Ferreira, A.C., Mahony, O., Hélio, E., Araujo, A., da Silva Costa, E. and Teleultrasound, F. (2015) Historical Perspective and Clinical Application. International Journal of Telemedicine and Applications, 2015, Article ID: 306259.
https://doi.org/10.1155/2015/306259
[8]
Le, K.D., Vuong, L.N., Ho, T.M., Dang, V.Q., Pham, T.D., Pham, C.T., Norman, R.J. and Mol, B. (2018) A Cost-Effectiveness Analysis of Freeze-Only or Fresh Embryo Transfer in IVF of Non-PCOS Women. Human Reproduction, 33, 1907-1914.
https://doi.org/10.1093/humrep/dey253
[9]
Wu, A.K., Elliott, P., Katz, P.P. and Smith, J.F. (2013) Time Costs of Fertility Care: The Hidden Hardship of Building a Family. Fertility and Sterility, 99, 2025-2030.
https://doi.org/10.1016/j.fertnstert.2013.01.145
[10]
Kelly, J., Hughes, C.M. and Harrison, R.F. (2006) The Hidden Costs of IVF. Irish Medical Journal, 99, 142-143.
[11]
Gerris, J., Geril, A. and De Sutter, P. (2009) Patient Acceptance of Self-Operated Endovaginal Telemonitoring (SOET): Proof of Concept. Facts, Views and Vision in Obstetrics and Gynaecology, 1, 161-170.
[12]
Vladimirov, I., Martin, V. and Desislava, T. (2021) P-670: Urine Estrone-3-Glucuronide (E3G) Assay: Is There Any Place during Ovarian Stimulation for IVF Cycles? Human Reproduction, 36, i1-i544. https://doi.org/10.1093/humrep/deab130.669
[13]
Fatemi, H., Bilger, W., Denis, D., Griesinger, G., La Marca, A., Longobardi, S., et al. (2021) Dose Adjustment of Follicle-Stimulating Hormone (FSH) during Ovarian Stimulation as Part of Medically-Assisted Reproduction in Clinical Studies: A Systematic Review Covering 10 Years (2007-2017). Reproductive Biology and Endocrinology, 19, Article No. 68.
[14]
Vargyas, J.M., Marrs, R.P., Kletzky, O.A. and Mishell, D.R. (1982) Correlation of Ultrasonic Measurement of Ovarian Follicle Size and Serum Estradiol Levels in Ovulatory Patients Following Clomiphene Citrate for in Vitro Fertilization. American Journal of Obstetrics & Gynecology, 144, 569-573.
https://doi.org/10.1016/0002-9378(82)90229-0
[15]
Suchanek, E., Huderera, K., Dobeca, D. and Grizelj, V. (1994) Number of Follicles, Oocytes and Embryos in Human in Vitro Fertilization Is Relative to Serum Estradiol and Progesterone Patterns during Different Types of Ovarian Hyperstimulation. European Journal of Obstetrics & Gynecology and Reproductive Biology, 56, 121-127. https://doi.org/10.1016/0028-2243(94)90268-2
[16]
Hull, M.E., Moghissi, K.S., Magyar, D.M., Hayes, M.F. and Zado, I. (1986) Correlation of Serum Estradiol Levels and Ultrasound Monitoring to Assess Follicular Maturation. Fertility and Sterility, 46, 42-46.
https://doi.org/10.1016/S0015-0282(16)49455-0
[17]
Roest, J., Verhoeff, A., van Heusden, A.M. and Zeilmaker, G.H. (1995) Minimal Monitoring of Ovarian Hyperstimulation: A Useful Simplification of the Clinical Phase of in Vitro Fertilization Treatment. Fertility and Sterility, 64, 552-556.
https://doi.org/10.1016/S0015-0282(16)57791-7
[18]
Wikland, M. and Hillensjo (2001) Monitoring IVF Cycles. In: Gardner, D., Wiessman, A., Howles, C. and Shoham, Z., Eds., Textbook of Assisted Reproductive Technologies: Laboratory and Clinical Perspectives, Martin Dinutz Publisher, Boca Raton, 501-504.
[19]
ESHRE (2019) Ovarian Stimulation for IVF/ICSI. Reproductive Endocrinology Guideline. https://www.eshre.eu/Guidelines-and-Legal
[20]
Broer, S.L., van Disseldorp, J., Broeze, K.A., Dolleman, M., Opmeer, B.C., Bossuyt, P., Eijkemans, M.J., Mol, B.W. and Broekmans, F.J. (2013) Added Value of Ovarian Reserve Testing on Patient Characteristics in the Prediction of Ovarian Response and Ongoing Pregnancy: An Individual Patient Data Approach. Human Reproduction Update, 19, 26-36. https://doi.org/10.1093/humupd/dms041
[21]
Zhu, X., Ye, H. and Fu, Y. (2017) Use of Utrogestan during Controlled Ovarian Hyperstimulation in Normally Ovulating Women Undergoing in Vitro Fertilization or Intracytoplasmic Sperm Injection Treatments in Combination with a ‘‘Freeze All’’ Strategy: A Randomized Controlled Dose-Finding Study of 100 mg versus 200 mg. Fertility and Sterility, 107, 379-386.e4.
https://doi.org/10.1016/j.fertnstert.2016.10.030
[22]
Chen, Q., Wang, Y., Sun, L., Zhang, S., Chai, W., Hong, Q., et al. (2017) Controlled Ovulation of the Dominant Follicle Using Progestin in Minimal Stimulation in Poor Responders. Reproductive Biology and Endocrinology, 15, 1-9.
https://doi.org/10.1186/s12958-017-0291-0
[23]
Ata, B., Capuzzo, M., Turkgeldi, E., Yildiz, S. and La Marca, A. (2021) Progestins for Pituitary Suppression during Ovarian Stimulation for ART: A Comprehensive and Systematic Review Including Meta-Analyses. Human Reproduction Update, 27, 48-66. https://doi.org/10.1093/humupd/dmaa040
[24]
Kolibianakis, E.M., Venetis, C.A., Kalogeropoulou, L., Papanikolaou, E. and Tarlatzis, B.C. (2011) Fixed versus Flexible Gonadotropin-Releasing Hormone Antagonist Administration in in Vitro Fertilization: A Randomized Controlled Trial. Fertility and Sterility, 95, 558-562. https://doi.org/10.1016/j.fertnstert.2010.05.052
[25]
Lainas, T., Zorzovilis, J., Petsas, G., Stavropoulou, G., Cazlaris, H., Daskalak, V., Lainas, G. and Alexopoulou, E. (2005) A Flexible Antagonist Protocol, Earlier, Criteria-Based Initiation of GnRH Antagonist Is Associated with Increased Pregnancy Rates in IVF. Human Reproduction, 20, 2426-2433.
https://doi.org/10.1093/humrep/dei106
[26]
Brianna, M., Schumacher, L., Mersereau, J.E. and Steiner, A.Z. (2018) Cycle Day, Estrogen Level, and Lead Follicle Size: Analysis of 27,790 in Vitro Fertilization Cycles to Determine Optimal Start Criteria for Gonadotropin-Releasing Hormone Antagonist. Fertility and Sterility, 109, 633-637.
https://doi.org/10.1016/j.fertnstert.2017.12.021
[27]
Olivennes, F., Belaisch-Allart, J., Emperaire, J.C., Dechaud, H., Alvarez, S., Moreau, L., Nicollet, B., Zorn, J.R., Bouchard, P. and Frydman, R. (2000) Prospective, Randomized, Controlled Study of in Vitro Fertilization-Embryo Transfer with a Single Dose of a Luteinizing Hormone-Releasing Hormone (LH-RH) Antagonist (Cetrorelix) or a Depot Formula of an LH-RH Agonist (Triptorelin). Fertility and Sterility, 73, 314-320. https://doi.org/10.1016/S0015-0282(99)00524-5
[28]
Honing Jr., R.V., Austin, C.W., Kuzma, D.L., Shapiro, S.S. and Zweibel, W.J. (1982) Ultrasound Evaluation of Estrogen Monitoring for Induction of Ovulation with Menotropins. Fertility and Sterility, 37, 627-632.
https://doi.org/10.1016/S0015-0282(16)46273-4
[29]
Tanabe, K., Susumu, N., Hand, K., Nishii, K., Ishikawa, I. and Nozawa, S. (2001) Prediction of the Potentially Fertile Period by Urinary Hormone Measurements Using a New Home-Use Monitor: Comparison with Laboratory Hormone Analyses. Human Reproduction, 16, 1619-1624. https://doi.org/10.1093/humrep/16.8.1619
[30]
Gerris, J., Annick, D.A., Dhont, N., Frank, V.F., Madoc, B., Magaly, B.M., et al. (2014) Self-Operated Endovaginal Telemonitoring versus Traditional Monitoring of Ovarian Stimulation in Assisted Reproduction: An RCT. Human Reproduction, 29, 1941-1948. https://doi.org/10.1093/humrep/deu168
[31]
Elnashar, A. (2010) Progesterone Rise on the Day of HCG Administration (Premature Luteinization) in IVF: An Overdue Update. Journal of Assisted Reproduction and Genetics, 27, 149-155. https://doi.org/10.1007/s10815-010-9393-8
[32]
Bosch, E., Labarta, E., Crespo, J., Simon, C., Remohi, J., Jenkins, J., et al. (2010) Circulating Progesterone Levels and Ongoing Pregnancy Rates in Controlled Ovarian Stimulation Cycles for in Vitro Fertilization: Analysis of over 4000 Cycles. Human Reproduction, 25, 2092-2100. https://doi.org/10.1093/humrep/deq125
[33]
Vandekerckhove, F., Gerris, J., Vansteelandt, S., De Baerdemaeker, A., Tilleman, K. and De Sutter, P. (2014) Delaying the Oocyte Maturation Trigger by One Day Leads to a Higher Metaphase II Oocyte Yield in IVF/ICSI: A Randomized Controlled Trial. Reproductive Biology and Endocrinology, 12, 31.
https://doi.org/10.1186/1477-7827-12-31
[34]
Santos-Ribeiro, S., Polyzos, N.P., Haentjens, P., Smitz, J., Camus, M., Tournaye, H. and Blockeel, C. (2014) Live Birth Rates after IVF Are Reduced by Both Low and High Progesterone Levels on the Day of Human Chorionic Gonadotrophin Administration. Human Reproduction, 29, 1698-1705.
https://doi.org/10.1093/humrep/deu151
[35]
Rottiers, A.S., Dalewyn, L., Somers, S., Alper, M.M., Sakkas, D. and Gerris, J. (2018) Correlation between Sonographic Follow-Up of Follicular Growth, Serum and Salivary Estradiol in Women Undergoing Controlled Ovarian Stimulation (IVF/ICSI). Facts, Views and Vision in Obstetrics and Gynaecology, 10, 173-179.
[36]
Sakkas, D., Howles, C.M.L., Atkinson, L., Borini, A., Bosch, E.A., Bryce, C., Cattoli, M., Copperman, A.B., de Bantel, A.F., French, B., Gerris, J., Granger, S.W., Grzegorczyk-Martin, V., Lee, J.A., Levy, M.J., Matin, M.J., Somers, S., Widra, E.A. and Alper, M.M. (2020) A Multi-Centre International Study of Salivary Hormone Oestradiol and Progesterone Measurements in ART Monitoring. Reproductive BioMedicine Online, 42, 421-428.
